Episode 1: When Should Treatment Start? What AML Patients Need to Know
Does delaying treatment impact survival? Dr. Samuel Yates helps us break down new research on treatment timing and what it means for patients making critical care decisions.
Thank you for listening! Reach out to Mary at mary@healthtree.org to share your thoughts.
To keep learning about today's topic, check out these additional resources mentioned in today's episode!
If you want to talk to other listeners about this episode, join HealthTree Connect below and start the conversation!
Mary Arnett
Mary joined HealthTree in 2022 as a part of HealthTree's team to help expand into all blood cancers. She now works as HealthTree's Volunteer & Community Outreach Manager, helping to engage and involve community members in HealthTree's mission. When she isn't working, she loves being the fun aunt to her 13 nieces and nephews, attending concerts, experimenting with new recipes in the kitchen, and traveling to explore new cities.
Dr. Samuel Yates
Dr. Yates is a researcher interested in hematologic malignancies (especially leukemias, like AML) in older adults, with a specific interest in the assessment and intervention of nutrition and body composition in these patients.